Will the IRay Revolutionize the Treatment of Wet Macular Degeneration?
April 9, 2010
Oraya Therapeutics, Inc. recently announced that a leading European notified body has granted approval to designate the CE mark to Oraya’s IRayTM stereotactic radiotherapy system. Under development since 2007, the IRay enables precise delivery of low energy X-rays for the treatment of wet age-related macular degeneration (AMD).
Clinical trials for the IRay are now underway in Europe, in the first-ever masked and sham-controlled study intended to demonstrate the efficacy and safety of radiation therapy for the treatment of AMD. The one time radiation treatment is given in conjunction with the current standard of care anti-VEGF drug regimen, and with the expectation that visual acuity outcomes for the treated patients will be maintained with significantly less frequent drug injections as compared to the sham controlled group.
Read the full release.
Comments
Jump down to form below to submit your own comments
